<DOC>
	<DOC>NCT00605111</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes failing OAD therapy.</brief_summary>
	<brief_title>Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes for at least 24 months BMI between 18 and 30 kg/m2 Insulin naive subjects OAD treatment with max two OADs alone or combined with other therapy HbA1c between 712% Type 1 diabetes Receipt of any investigational drug within the last three months prior to this trial Current or previous treatment with thiazolidiones within the last 6 months OAD treatment with three or more OADs within the last 4 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>